N-acetylcysteine augmentation in treatment-resistant obsessive-compulsive disorder: a randomized double-blind placebo-controlled trial
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG
Published in Journal of Clinical Psychiatry
Methodology
Randomized double-blind placebo-controlled trial of NAC 3000 mg daily added to standard treatment in adults with treatment-resistant OCD.
Key Findings
NAC did not outperform placebo on the primary Yale-Brown obsessive-compulsive scale outcome, though anxiety scores improved.
Conclusions
A well-powered trial found no benefit of NAC for core obsessive symptoms.
Limitations
Single centre; treatment-resistant sample may limit generalisability.
Supplements Studied
NAC did not outperform placebo on the primary Yale-Brown obsessive-compulsive scale outcome
Outcomes Measured
NAC did not outperform placebo on the primary Yale-Brown obsessive-compulsive scale outcome
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.